<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05004961</url>
  </required_header>
  <id_info>
    <org_study_id>XW-MMPET-001</org_study_id>
    <nct_id>NCT05004961</nct_id>
  </id_info>
  <brief_title>The Performance of Multi-tracer Multimodality PET in Lymphoma</brief_title>
  <official_title>The Performance of Multi-tracer Multimodality PET in Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigating the performance of Multi-tracer Multimodality PET in lymphoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study investigators evaluated Nodal and Extranodal Lymphoma Lesions uptake by&#xD;
      different molecular probe such as FDG, FAPI-04 via multimodality PET (PET/CT and PET/MR). Our&#xD;
      Previous studies have shown that uptake of FAPI-04 on PET may be an indicator of lymphoma&#xD;
      lesions. The combination of PET with CT/MR allows for depicting metabolic, functional and&#xD;
      morphological properties of tumor lesions at the same time, which is therefore an alternative&#xD;
      attractive pairing for diagnosis, staging and prognosis of lymphoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>SUVmax</measure>
    <time_frame>150 days</time_frame>
    <description>Standardized uptake value of 68Ga/ 18F-NOTA-FAPI 04 for target lesion of subject or suspected tumor in each time point window (SUV)</description>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Positron-Emission Tomography</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients pathologically diagnosed as lymphoma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  pathologically diagnosed as lymphoma;&#xD;
&#xD;
          -  Written informed consent for receiving FAPI-04 PET examinations.&#xD;
&#xD;
          -  cancer planned chemotherapy or immunotherapy scheme.&#xD;
&#xD;
          -  expected survival â‰¥ 12 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  cannot lie supine for half an hour;&#xD;
&#xD;
          -  refuse to join the clinical researcher;&#xD;
&#xD;
          -  severe liver or kidney dysfunction&#xD;
&#xD;
          -  pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yang Zhi, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xuejuan Wang, MD</last_name>
    <phone>86 010 88196363</phone>
    <email>xuejuan_wang@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuejuan Wang, MD</last_name>
      <phone>86 10-88196363</phone>
      <email>xuejuan_wang@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 7, 2021</study_first_submitted>
  <study_first_submitted_qc>August 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Xuejuan Wang,MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Positron-Emission Tomography</keyword>
  <keyword>Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

